<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, have revealed few side effects associated with its use </plain></SENT>
<SENT sid="1" pm="."><plain>We here report a case of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> associated with the development of neutralizing antibodies to TPO that occurred in a patient who had undergone multicycle chemotherapy with multiple cycles of subcutaneous administration of pegylated recombinant human megakaryocyte growth and development factor </plain></SENT>
<SENT sid="2" pm="."><plain>Samples of the patient's bone marrow showed trilineage <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> with absence of myeloid, erythroid, and megakaryocyte progenitor cells but with elevated endogenous levels of erythropoietin, granulocyte colony-stimulating factor, and stem-cell factor </plain></SENT>
<SENT sid="3" pm="."><plain>To our knowledge, this is the first report of an <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>-like syndrome associated with neutralizing antibodies to TPO </plain></SENT>
</text></document>